检索结果-南通市图书馆

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Radiation Medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation oncology China Anti-cancer Association Branch of Radiation oncology Chinese Medical Association Branch of Radiation oncology TreatmentPhysician Chinese Medical Doctor Association Qingsong Pang Jun Wang Zhouguang Hui Wencheng Zhang 不详 Tianjin Medical university cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical university Shijiazhuang 050011China National cancer center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Tianjin Medical university cancer Hospital China

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation oncology,China Anti-cancer Association,the Branch of Radiation oncology,Chinese Medical Association,and the Branch of Radiation oncology Treatment Physician,Chinese Medical Doctor Association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

Growth suppression and radiosensitivity increase by HMGB1 in breast cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2007年第12期28卷 1957-1967页

作者： Yang JIAO~2,Hai-chao WANG~3,Sai-jun FAN~(2,4,5)~2 School of Radiology and Public Health,Soochow university,Suzhou 215123,China ~3 department of Emergency Medicine,North Shoreuniversity Hospital,New York university School of Medicine,Manhasset,New York 11030,usa ~4 department of oncology,lombardicomprehensive cancer center,georgetown university,washington dc,washington 20057,usa School of Radiology and Public Health Soochow UniversitySuzhou 215123China department of Emergency Medicine North Shore University HospitalNew York University School of MedicineManhassetNew York 11030USA department of oncology Lombardi Comprehe

Aim:HMGB 1 （high-mobility group box-1） is a nuclear protein containing a con-sensus RB （retinoblastoma）-binding LXCXE *** this study,we studied thepotential association of HMGB 1 and RB and the in vitro and in vivo activities ofHMGB 1 in human breast cancer ***:The protein-protein interactionwas determined by immunoprecipitation-Western blotting and glutathione-S-trans-ferase capture assays;cell growth and radiosensitivity were examined by cellcounts,MTT assay,and clonogenic assay;cell cycle progression and apoptosiswere evaluated using flow cytometry;and the antitumor activity of HMGB 1 wasexamined with tumor xenografts in nude ***:HMGB 1 was associatedwith RB via a LXCXE motif-dependent *** 1 enhanced the abilityof RB for E2F and cyclin A transcription *** increased expression ofHMGB 1 conferred an altered phenotypes characterized by the suppression of cellgrowth;G1arrest and apoptosis was induced in MCF-7 cells containing the wild-type retinoblastoma （Rb） gene,but showed no activities in BT-549 cells contain-ing the Rb gene *** HMGB 1-induced apoptosis accompanied by caspase3 activation and PARP (poly（ADP-ribose）polymerase) *** 1 elevatedthe radiosensitivity of breast cancer cells in both the MCF-7 and BT-549 cell *** enhanced expression of HMGB 1 caused a suppression of growth of MCF-7tumor xenografts in nude mice,while LXCXE-defective HMGB 1 completely lostantitumor growth ***:HMGB 1 functions as a tumor suppressorand radiosensitizer in breast cancer.A HMGB 1-RB interaction is critical for theHMGB 1-mediated transcriptional repression,cell growth inhibition,G1cell cyclearrest,apoptosis induction,and tumor growth suppression,but is not required ***,it may be possible to design new therapies for thetreatment of breast cancer that exert their effects by modulating the HMGB 1 andRB regulatory pathway and HMGB 1-related gene therapy.

关键词： HMGBI RB breast cancer cell growth

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

电磁实时追踪系统质控实践指南

中华放射肿瘤学杂志 2024年第2期33卷 93-102页

作者：国家癌症中心/国家肿瘤质控中心何侠不详江苏省肿瘤医院/江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院放疗科南京210009

个体化、精准化放射治疗时代对肿瘤运动管理提出了更高的要求,电磁实时追踪系统即为有代表性的肿瘤运动管理技术。该技术涉及的人员、流程较多,质量控制也不同于一般的放射治疗质控实践,因此制定了本质控实践指南。本指南为开展电磁实... 详细信息

个体化、精准化放射治疗时代对肿瘤运动管理提出了更高的要求,电磁实时追踪系统即为有代表性的肿瘤运动管理技术。该技术涉及的人员、流程较多,质量控制也不同于一般的放射治疗质控实践,因此制定了本质控实践指南。本指南为开展电磁实时追踪系统的机构提供组织、人员、设备、技术流程及文档记录等方面的质量控制标准,内容涵盖系统介绍、适应证选择及患者宣教、信标转发器植入流程及质控、日检、月检和文档记录。基于本指南,可以满足电磁实时追踪系统质控实践的各项标准要求。

关键词：放射疗法电磁实时追踪运动管理立体定向放射疗法质量控制

在线全文

学校读者我要写书评

暂无评论

放射治疗相关的器官运动管理指南

中华放射肿瘤学杂志 2024年第3期33卷 189-196页

作者：国家癌症中心/国家肿瘤质控中心陈明不详华南恶性肿瘤防治全国重点实验室广东省鼻咽癌诊治研究重点实验室广东省恶性肿瘤临床医学研究中心中山大学肿瘤防治中心中山大学-国科离子放射治疗前沿技术联合实验室广州510060

肿瘤定位的准确性是实现精准放射治疗的关键。器官运动是肿瘤定位的主要误差来源。不同部位肿瘤的运动类型不同,相应的管理策略也有所差异。本指南系统总结了头颈部、胸部、腹部、盆腔部的常见肿瘤疾病的器官运动来源,以及现行的运动管... 详细信息

肿瘤定位的准确性是实现精准放射治疗的关键。器官运动是肿瘤定位的主要误差来源。不同部位肿瘤的运动类型不同,相应的管理策略也有所差异。本指南系统总结了头颈部、胸部、腹部、盆腔部的常见肿瘤疾病的器官运动来源,以及现行的运动管理方法。针对基于医用电子直线加速器开展的放射治疗,本指南依据肿瘤所处的部位差异,给出了相应的运动管理建议,旨在为已开展或即将开展放射治疗临床实践的单位提供参考的指南依据,以便正确、合理地制订器官运动管理方案,提升放疗实施的准确性,保证治疗疗效。

关键词：放射疗法器官运动管理指南

Adenovirus-mediated expression of Tob1 sensitizes breast cancer cells to ionizing radiation

在线全文

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2007年第10期28卷 1628-1636页

作者： Yang JIAO~2,Chun-min GE~3,Qing-hui MENG~2,Jian-ping CAO~2,Jian TONG~2,Sai-jun FAN~(2,3,4)~2 School of Radiology and Public Health,Soochow university,Suzhou 215123,China,~3 department of oncology,Lombardi Comprehensive cancercenter,georgetown university,washington dc 20057,usa School of Radiology and Public Health Soochow University Suzhou 215123 China department of oncology Lombardi Comprehensive Cancer Center Georgetown University Washington 20057 DC USA

Aim:To investigate the effect of the Tob1 gene,a member of the TransducingMolecule of ErbB2/B-cell Translocation Ggene (TOB/BTG) family,by usingthe adenovirus-mediated expression of Tob 1 on radiosensitivity in a human breastcancer cell line ***:Cell survival was determined byclonogenic *** was evaluated by DNA fragmentation gel electro-phoresis and terminal deoxynucleotidyl transferase-mediated nick end *** expression was analyzed by Western blot assay and DNA repairwas measured by a host cell reactivation ***:We demonstrated thatpre-irradiation treatment with Ad5-Tob 1 significantly increased radiosensitivity,accompanying the increased induction of apoptosis and the repression of DNAdamage ***,Ad5-Tob 1-mediated radiosensitivity correlates withthe upregulation of the pro-apoptotic protein Bax and the downregulation ofseveral DNA double strand break repair proteins,including DNA-dependent pro-tein kinases,Ku70 and Ku80,and X-ray-sensitive complementation group ***:Tob1,as a new radiosensitizer,is a new target in the radiotherapyof breast cancer via increasing apoptosis and suppressing DNA repair.

关键词： Tobl breast cancer radiosensitivity radiation

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

蕈样霉菌病全身皮肤放射治疗临床指南

中华放射肿瘤学杂志 2024年第8期33卷 687-697页

作者：国家癌症中心/国家肿瘤质控中心夏云飞不详中山大学肿瘤防治中心广州510060

蕈样肉芽肿病(MF,又称蕈样霉菌病)/Sezary综合征是皮肤T细胞淋巴瘤的一种。全身皮肤照射已经被证明是一种治疗皮肤MF的有效方式。既往一般使用电子线治疗,全身皮肤电子治疗剂量与处方剂量的偏差高达40%。随着放疗技术的进步,光子螺旋断... 详细信息

蕈样肉芽肿病(MF,又称蕈样霉菌病)/Sezary综合征是皮肤T细胞淋巴瘤的一种。全身皮肤照射已经被证明是一种治疗皮肤MF的有效方式。既往一般使用电子线治疗,全身皮肤电子治疗剂量与处方剂量的偏差高达40%。随着放疗技术的进步,光子螺旋断层放射治疗在技术上可以代替电子线治疗,其优点包括:明显改善剂量均匀性、不存在射野衔接、患者在更加舒适的仰卧位进行治疗。本文根据中山大学肿瘤防治中心的治疗数据,联合多家放射治疗中心,就光子螺旋断层放射治疗MF,从物理、技术、临床三个方面,对体位固定、CT模拟定位、放疗计划设计和剂量处方等放射治疗的各个环节,提供尽量统一的规范和标准,共各医疗单位参考,使MF患者获得最为合理的放射治疗。

关键词：蕈样真菌病光子螺旋断层放射疗法全身皮肤照射淋巴瘤,T细胞

在线全文

学校读者我要写书评

暂无评论

原发性三叉神经痛靶区勾画和计划设计指南

中华放射肿瘤学杂志 2024年第7期33卷 585-598页

作者：国家癌症中心/国家肿瘤质控中心潘隆盛不详解放军总医院第一医学中心神经外科医学部北京100853

立体定向放射外科是原发性三叉神经痛的重要治疗方式。规范开展放射外科治疗对患者疼痛的控制和生活质量的提高具有重要意义。本指南涵盖了基于伽玛刀、射波刀等不同系统下原发性三叉神经痛放射外科治疗过程的全流程质量标准,包括靶区... 详细信息

立体定向放射外科是原发性三叉神经痛的重要治疗方式。规范开展放射外科治疗对患者疼痛的控制和生活质量的提高具有重要意义。本指南涵盖了基于伽玛刀、射波刀等不同系统下原发性三叉神经痛放射外科治疗过程的全流程质量标准,包括靶区定位和勾画、计划设计与优化、危及器官剂量限制和疼痛复发的影响因素及处理方式。以期基于不同单位实际条件及患者治疗情况,提高各级放疗单位针对原发性三叉神经痛放射外科治疗的规范化水平。

关键词：三叉神经痛,原发性立体定向放射外科靶区勾画放疗计划医学实践指南

在线全文

学校读者我要写书评

暂无评论

肿瘤放射治疗质量安全评价标准指南

中华放射肿瘤学杂志 2024年第4期33卷 281-295页

作者：国家癌症中心/国家肿瘤质控中心陈传本不详福建医科大学肿瘤临床医学院福建省肿瘤医院/福建省肿瘤质控中心福州350014

目前各地区不同级别的放疗单位中,临床治疗流程、人员资质和结构、设备的配置和状态、质控水平尚不统一,多数省级质控中心尚无可量化、客观化的质量安全评价标准进行放疗质量安全和质控水平的评价。这影响了省级质控中心对本省放疗单位... 详细信息

目前各地区不同级别的放疗单位中,临床治疗流程、人员资质和结构、设备的配置和状态、质控水平尚不统一,多数省级质控中心尚无可量化、客观化的质量安全评价标准进行放疗质量安全和质控水平的评价。这影响了省级质控中心对本省放疗单位的质控管理、质量安全和质控水平进行检查、监督和评价,也影响国家肿瘤质控中心对全国放疗单位质控水平进行同质化评估。鉴于此,本指南系统介绍肿瘤放射治疗质量安全的评价项目、评价要点、检查要素和评价对象等内容,以期建立适用各级放疗单位的放疗质量安全评价标准体系,搭建同质化平台,以解决当前不同省份、不同级别的医院质量保证难以监控的实际问题,为各级放疗质控中心的质控评价和质量安全管理提供统一的、有效的评价标准。

关键词：放射疗法质量安全评价项目评价要点检查要素评价对象

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of Clinical oncology(CSCO) Expert Committee on Leukemia of Chinese Society of Clinical oncology(CSCO) Society of Integrative Cardio-oncology of China Anti-cancer Association(CACA) Chinese Society of Hematology of Chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association(SMEA) department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology center Peking UniversityBeijing 100191China department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China department of Hematology and oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions